Skip to main content
SpringerLink
Log in

Budipin

  • Chapter
Neuro-Psychopharmaka Ein Therapie-Handbuch

  • 87 Accesses

Zusammenfassung

Die Degeneration des nigrostriatalen dopa-minergen Systems wird als charakteristisch für den Morbus Parkinson angesehen. Die komplexe Symptomatologie der Erkrankung weist darauf hin, daß auch andere Neurotransmittersysteme wie das cholinerge, noradrenerge, serotonerge, glutamaterge und peptiderge System neben der Symptomausprägung von Rigor, Tremor und Akinese eine Rolle spielen (Przuntek 1992). Aufgrund seines pharmakologischen Profils beeinflußt Budipin neben dem dopaminergen System auch das noradrenerge, serotonerge, glutamaterge und cholinerge System und stellt somit in der medikamentÖsen Therapie des Morbus Parkinson einen weiteren therapeutischen Ansatz dar (zur übersicht: Müller 1998). Budipin ist ein 4,4-Diphenylpiperidin (Hacknack et al. 1979). In tierexperimentellen Untersuchungen zeigte Budipin eine ErhÖhung von Vigilanz und Aktivierungsbereitschaft ohne Steigerung der Mobilität, eine Hemmung experimentell provozierter Tremorzustände und eine Minderung von experimentell induziertem Rigor und Akinese (Menge und Brand 1982, 1985).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 64.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Bonnet AM, Loria Y, Saint Hilaire MR, Lhermitte F, Agid Y (1987) Does long-term aggravation of Parkinson’s disease result from non-dopaminergic lesions? Neurology 37: 1539–1542

    Article  PubMed  CAS  Google Scholar 

  • Bowman CE (1995) Drug-licensing aromalies and Parkinson’s disease. Lancet 345: 517

    Article  PubMed  CAS  Google Scholar 

  • Braak H, Braak E, Yilmazer D, de Vos RAI, Jansen ENH (1995) Nigral and extranigralpathology in parkinson’s disease. J Neural Transm 46 [Suppl]: 15–32

    CAS  Google Scholar 

  • Brandt T, Paulus W, Pollmann W (1991) Cluster headache and chronic paroxysmal hemicrania: current therapy. Nervenarzt 62: 329–339

    PubMed  CAS  Google Scholar 

  • Dimpfel W, Spuler M, Menge HG (1989) Effects of the antiparkinson drug budipine on EKG-activity in unrestrained rats. Arzneimittelforschung 39: 560–563

    PubMed  CAS  Google Scholar 

  • Gade G (1992) Erfahrungen mit Budipin in der Langzeittherapie. Dissertation, Universität Hamburg

    Google Scholar 

  • Hacknack G, Menge HG, Eistetter K, Krüger U, Schäefer H, Klosa J (1979) 4,4-Diphenylpipe-ridine — ein neuer Substanztyp für die Therapie des Morbus Parkinson. Österr Chemie Z 4: 61–62

    Google Scholar 

  • Iizuka J (1985) Controlled single-blind trial of budipine, L-Dopa and amantadine in 102 patients with parkinson’s disease. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experience with budipine. Springer, Berlin Heidelberg New York Tokyo, pp 129–139

    Chapter  Google Scholar 

  • Iizuka J, Fischer R (1986) Modification of Parkinson tremor by budipine. A comparative study with amantadine. Nervenarzt 57: 184–186

    CAS  Google Scholar 

  • Jackisch R, Huang MY, Reimann W, Limberger N (1993) Effects of the antiparkinsonian drug budipine on neurotransmitter release in central nervous system tissue in vitro. J Pharmacol Exp Ther 26: 889–898

    Google Scholar 

  • Jackisch R, Kruchen A, Sauermann W, Hertting G, Feuerstein TJ (1994) Theantiparkinsonian drugs budipine and biperiden are use-dependent (uncompetitive) NMDA-receptor antagonists. Eur J Pharmacol 264: 207–211

    Article  PubMed  CAS  Google Scholar 

  • Jellinger K, Bliesath H (1987) Adjuvant treatment of Parkinson’s disease with budipine: a double-blind trial versus placebo. J Neurol 234: 280–282

    Article  PubMed  CAS  Google Scholar 

  • Ketz E (1985) Open clinical trial of budipine in 25 tremor-dominant Parkinsonian patients. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experience with budipine. Springer, Berlin Heidelberg New York Tokyo, pp 140–141

    Chapter  Google Scholar 

  • Klockgether T, Jacobsen P, Loschmann PA, Turski L (1993) The antiparkinsonian agent budipine is an N-methyl-D-aspartate antagonist. J Neural Transm [PD Sect] 5: 101–106

    Article  CAS  Google Scholar 

  • König P, Pass-Kosmath I (1985) Randomized double blind trial of budipine and biperiden inpatients with neurolepic extrapyramidal symptoms. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experiences with budipine in Parkinson therapy. Springer, Berlin Heidelberg New York Tokyo, pp 176–181

    Chapter  Google Scholar 

  • Kornhuber J, Herr B, Thome J, Riederer P (1995) The antiparkinsonian drug budipine binds to NMDA and sigma receptors in post mortem brain tissue. J Neural Transm [Suppl] 46: 131–137

    CAS  Google Scholar 

  • Krafczyk S, Hökendorf H (1985) EMG and computer analysis of patients with tremor and rigidity under Budipine therapy. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experience with budipine. Springer, Berlin Heidelberg New York Tokyo, pp 185–193

    Chapter  Google Scholar 

  • Krüger H, Kohlhepp W, Reimann G, Przuntek H (1988) Prophylactic treatment of cluster headache with budipine. Headache 28: 344–346

    Article  PubMed  Google Scholar 

  • Kuhn W, Russ H, Dettner O, Gerlach M, Przuntek H (1987) Interactions of deprenyland budipine with MAO-B in vivo and in vitro. Neuroscience 22: 527

    Google Scholar 

  • Kuhn W, Müller TH (1997) Clinical efficacy of Budipine in Parkinson’s disease (submitted)

    Google Scholar 

  • Lloyd KG, Davidson L, Hornykiewicz O (1975) The neurochemistry of Parkinson’s disease: effect of L-dopa therapy. J Pharmacol Exp Ther 195: 453–464

    PubMed  CAS  Google Scholar 

  • Menge H, Brand U (1982) Zusammenfassende Darstellung der Pharmakologie von Budipin, einem neuen 4,4-Diphenylpiperidinderivat für die Parkinson-Therapie. Drug Res 32: 85–98

    CAS  Google Scholar 

  • Menge HG, Brand U (1985) Pharmacologic bases of antiparkinsonian therapy. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experiences with budipine in Parkinson therapy. Springer, Berlin Heidelberg New York Tokyo, pp 82–92

    Chapter  Google Scholar 

  • Mihatsch W, Russ H, Przuntek H (1988) Intracer-ebroventricular administration of 1-methyl-4-phenylpyridinium ion in mice: effects of simultaneously administered nomifensine, deprenyl, and l-t-butyl-4,4-diphenylpiperidine. J Neural Transm 71: 177–188

    Article  PubMed  CAS  Google Scholar 

  • Müller D (1985) Budipine in the treatment of extrapyramidal disorders not related to Parkinson’s disease. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experience with budipine. Springer, Berlin Heidelberg New York Tokyo, pp 203–210

    Chapter  Google Scholar 

  • Müller TH (1998) Budipin. Akt Neurol 25: 310–318

    Article  Google Scholar 

  • Niznik HB, Tyndale RF, Sallee FR, Gonzales FJ, Hardwick JP, Inaba T, Kalow W (1990) The dopamine transporter and cytochrome P450IID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct (3H)GBR-12935 binding proteins. Arch Biochem Biophys 276: 424–432

    Article  PubMed  CAS  Google Scholar 

  • Oppel F (1985) Long term treatment with Budipine. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experience with budipine. Springer, Berlin Heidelberg New York Tokyo, pp 185–193

    Google Scholar 

  • Poewe W, Gerstenbrand F, Ransmayr G (1985) In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experience with budipine. Springer, Berlin Heidelberg New York Tokyo, pp 122–128

    Chapter  Google Scholar 

  • Przuntek H (1992) Krankheiten der Basalganglien. In: Kunze K (Hrsg) Lehrbuch der Neurologic Thieme, Stuttgart New York, S 374–403

    Google Scholar 

  • Przuntek H, Russ H (1985) Budipine and the MPTP binding site. Lancet ii: 35–36

    Article  Google Scholar 

  • Przuntek H, Russ H, Henning K, Pindur U (1985) The protective effect of l-tert.butyl-4,4-di-phenylpiperidine against the nigrostriatal neurodegeneration caused by l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine. Life Sci 37: 1195–1200

    Article  PubMed  CAS  Google Scholar 

  • Riederer P, Wuketich S (1976) Time course of nigrostriatal degeneration in Parkinson’s disease. J Neural Transm [Gen Sect] 38: 277–301

    Article  CAS  Google Scholar 

  • Russ H, Pindur U, Przuntek H (1986) The interaction of l-alkyl-4,4-diphenylpiperidines with the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine receptor binding site. J Neural Transm 65: 157–166

    Article  PubMed  CAS  Google Scholar 

  • Schaffler K (1985) Vigilance study using electrooculographic and electroencephalographic methods after acute budipine administration in healthy subjects. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experience with budipine. Springer, Berlin Heidelberg New York Tokyo, pp 194–202

    Chapter  Google Scholar 

  • Schaefer H, Hackmack G, Eistetter K, Kruger U, Menge HG, Klosa J (1984) Svnthesis, physical-chemical properties and pharmacologically-oriented screening studies on budipine and related 4,4-diphenylpiperidines. Arzneimittelforschung 34: 233–240

    PubMed  CAS  Google Scholar 

  • Spieker S, Löschmann P, Jentges C, Boose A, Klockgether T, Dichgans J (1995) Tremorlytic activity of budipine: a quantitative study with long-term tremor recordings. Clin Neuropharmacol 18: 266–272

    Article  PubMed  CAS  Google Scholar 

  • Stasch JP, Russ H, Schacht U, Witteler M, Neuser D, Gerlach M, Leven M, Kuhn W, Jutzi P, Przuntek H (1988) 4,4-Diphenylpiperidine derivates and their sila analogues. A comparative study of their interaction with neural receptor binding sites and synaptosomal monoamine uptake. Arzneimittelforschung 38: 1075–1078

    PubMed  CAS  Google Scholar 

  • Ulm G (1985) Effect of Budipine on parkinsonian tremor resistent to other antiparkinsonian medication. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experience with budipine. Springer, Berlin Heidelberg New York Tokyo, pp 142–151

    Chapter  Google Scholar 

  • Vaugeois JM, Bonnet JJ, Duterte Boucher D, Costentin J (1993) In vivo occupancy of the striatal dopamine uptake complex by various inhibitors does not predict their effects on locomotion. Eur J Pharmacol 230: 195–201

    Article  PubMed  CAS  Google Scholar 

  • Xinde W (1985) Observations on the therapeutic effect of budipine on Parkinson’s disease. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experience with budipine. Springer, Berlin Heidelberg New York Tokyo, pp 158–162

    Chapter  Google Scholar 

  • Zech K, Sturm E, Ludwig G (1985) Pharmacokinetics and metabolism of budipine in animals and humans. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experience with budipine. Springer, Berlin Heidelberg New York Tokyo, pp 113–121

    Chapter  Google Scholar 

Download references

Authors
  1. Th. Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Kuhn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Przuntek
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinische Neurochemie, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Würzburg, Bundesrepublik Deutschland

    Peter Riederer

  2. Bezirkskrankenhaus Gabersee, Wasserburg/Inn, Bundesrepublik Deutschland

    Gerd Laux

  3. Wien, Österreich

    Walter Pöldinger

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag Wien

About this chapter

Cite this chapter

Müller, T., Kuhn, W., Przuntek, H. (1999). Budipin. In: Riederer, P., Laux, G., Pöldinger, W. (eds) Neuro-Psychopharmaka Ein Therapie-Handbuch. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6400-6_32

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-6400-6_32

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-7315-2

  • Online ISBN: 978-3-7091-6400-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation